Precision BioLogic Promotes Hemostasis Diagnostics
Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The event is a promotional and educational effort by Precision BioLogic, which may modestly raise its profile among hemostasis clinicians and researchers. It does not directly affect major market indices or the stock prices of large pharmaceutical companies, but could support demand for Precision BioLogic's diagnostic products as new hemophilia treatments advance.
Precision BioLogic Inc., a developer of hemostasis diagnostic products, and its subsidiaries Precision BioLogic — Affinity Biologicals and Precision BioLogic — George King Bio-Medical, are promoting their combined expertise in hemostasis diagnostics and research. The company highlighted its CRYOcheck Chromogenic Factor VIII assay, which is designed to accurately measure factor VIII in the presence of emerging hemophilia treatments such as Mim8, a bispecific antibody developed by Novo Nordisk. Interest has increased following Novo Nordisk's submission of Mim8 to the United States — Food and Drug Administration. Precision BioLogic exhibited at the ISTH 2026 congress in Paris, presented two scientific posters, showcased manufacturing capabilities at ADLM 2026, and engaged with the bleeding disorders community at the NBDF conference. The company aims to ensure coagulation labs are prepared for new therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard